Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Breast cancer surgery: Study finds overnight hospital stay not important for older patients

2.

To automate the biopharmaceutical facilities of Reliance Life Sciences, ABB India has won the contract.

3.

Immunotherapy Is As Safe As Other Cancer Treatments During Pregnancy.

4.

‘Bar Code’ Biopsy From RNA Could Guide Precision Oncology

5.

Blinatumomab Plus Chemotherapy New Standard for Children With B-Cell ALL


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot